Literature DB >> 21040209

Middle cerebral artery-peak systolic velocity in dizygotic twins with anti-E alloimmunization.

Yumiko Satake1, Yukiyasu Sato, Noriomi Matsumura, Keiji Tatsumi, Hiroshi Fujiwara, Ikuo Konishi.   

Abstract

Middle cerebral artery-peak systolic velocity (MCA-PSV) has been reported to predict fetal anemia with similar accuracy as amniotic ΔOD450 assay. Alloimmunized dizygotic twin pregnancy allows us to compare anemic and non-anemic twins in the same intrauterine environment. We herein present a case of Rh (E)-incompatible dizygotic twin pregnancy, where MCA-PSV could precisely detect the anemia in one of the twins. A 36-year-old woman, whose previous child required exchange transfusion due to hemolytic anemia of newborn (HFDN), conceived twins after in vitro fertilization-embryo transfer. At 24 weeks' gestation, MCA-PSV of twin A and twin B were 23.9 cm/s (0.8 multiples of median; MoM) and 30.7 cm/s (1.0 MoM), respectively. At 31 weeks' gestation, MCA-PSV values of both twins were sharply elevated to nearly 1.4 MoM. Thereafter, MCA-PSV of twin A fell to 1.0 MoM, whereas MCA-PSV of twin B exceeded 1.5 MoM at 34 weeks' gestation. Development of fetal anemia was suspected and emergency cesarean section was performed. Twin B showed moderate anemia with positive direct Coombs' test and was diagnosed as HFDN due to anti-E alloimmunization. Twin B required phototherapy and red cell transfusion, but exchange transfusion was safely obviated.
© 2010 The Authors. Journal of Obstetrics and Gynaecology Research © 2010 Japan Society of Obstetrics and Gynecology.

Entities:  

Mesh:

Year:  2010        PMID: 21040209     DOI: 10.1111/j.1447-0756.2010.01314.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  1 in total

1.  Retrospective analysis of 55 twin neonates with haemolytic disease of the newborn.

Authors:  Hu Zhao; Bijuan Li; Ning Li; Yamei Shen; Kailiang Liu; Xiangwu Shu; Cheng Mei; Lanlan Tang
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.